FrancophonIA/ELRC3.0 huggingface dataset:
English: In non-valvular atrial fibrillation patients taking apixaban for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels.
Croatian: U bolesnika s nevalvularnom atrijskom fibrilacijom koji uzimaju apiksaban za prevenciju moždanog udara i sistemske embolije, rezultati pokazuju da je fluktuacija između najviše i najniže razine manja od 1,7 puta.
English: Each 5 mg film-coated tablet contains 102.86 mg lactose (see section 4.4).
Croatian: Pomoćne tvari s poznatim učinkom Jedna filmom obložena tableta od 5 mg sadrži 102,86 mg laktoze (vidjeti dio 4.4).
English: Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability (see section 5.1).
Croatian: Kod primjene uobičajne terapijske doze lijeka uočene promjene u rezultatima navedenih testova zgrušavanja su male i podložne visokom stupnju varijabilnosti (vidjeti dio 5.1).
English: For patients randomised to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%.
Croatian: U bolesnika randomiziranih da primaju varfarin, medijan postotka vremena provedenog u terapijskom rasponu (engl. time in therapeutic range, TTR) (INR 2-3) bio je 66%.
English: Corresponding increases in clotting tests were observed for apixaban.
Croatian: Opažene su odgovarajuće promjene rezultata testova zgrušavanja za apiksaban.
English: For patients who are unable to swallow whole tablets, Eliquis tablets may be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally (see section 5.2).
Croatian: Za bolesnike koji ne mogu progutati cijele tablete, tablete Eliquis mogu se zdrobiti i suspendirati u vodi, ili 5%-tnoj otopini glukoze u vodi, ili u soku od jabuke ili pomiješati s pireom od jabuke te odmah primijeniti peroralno (vidjeti dio 5.2).
English: Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery (VTEp)
Croatian: Prevencija VTE u odraslih bolesnika podvrgnutih elektivnom kirurškom zahvatu ugradnje endoproteze kuka ili koljena (VTEp)
English: This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
Croatian: To može uključivati sadašnju ili nedavnu gastrointestinalnu ulceraciju, prisutnost malignih novotvorina kod kojih postoji velik rizik od krvarenja, nedavne ozljede mozga ili kralježnice, nedavni kirurški zahvat na mozgu, kralježnici ili očima, nedavno intrakranijalno krvarenje, utvrđene ili suspektne varikozitete jednjaka, arteriovenske malformacije, vaskularne aneurizme ili značajne abnormalnosti intraspinalnih ili intracerebralnih krvnih žila.
English: Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.
Croatian: Stoga, primjena aktivnog ugljena može biti korisna u slučaju predoziranja apiksabanom ili nehotičnog uzimanja lijeka.
English: - Blood tests may show: - abnormal liver function - an increase in some liver enzymes - an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.
Croatian: - Krvna slika može pokazati: - poremećaj jetrene funkcije - povišene vrijednosti nekih jetrenih enzima - povišene vrijednosti bilirubina, koji nastaje razgradnjom crvenih krvnih stanica i zbog kojeg koža i oči mogu poprimiti žutu boju.
English: Alternatively, Eliquis tablets may be crushed and suspended in 60 mL of water or D5W and immediately delivered through a nasogastric tube (see section 5.2).
Croatian: Alternativno, tablete Eliquis mogu se zdrobiti i otopiti u 60 ml vode ili 5%-tne glukoze u vodi i odmah primijeniti putem nazogastrične sonde (vidjeti dio 5.2).
English: The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Apixaban is rapidly absorbed with maximum concentrations (Cmax) appearing 3 to 4 hours after tablet intake.
Croatian: Apiksaban se brzo apsorbira, a maksimalne koncentracije (Cmax) postiže 3 do 4 sata nakon uzimanja tablete.
English: Anticoagulants, platelet aggregation inhibitors, SSRIs/SNRIs and NSAIDs Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated except under specific circumstances of switching anticoagulant therapy, when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation (see section 4.3).
Croatian: Antikoagulansi, inhibitori agregacije trombocita, SSRI-jevi/SNRI-jevi i NSAIL-ovi Zbog povećanog rizika od krvarenja istodobno liječenje bilo kojim drugim antikoagulansom je kontraindicirano osim u posebnom slučaju promjene antikoagulantne terapije kada se nefrakcionirani heparin daje u dozama nužnima za održavanje centralnog venskog ili arterijskog katetera otvorenim ili kada se nefrakcionirani heparin daje tijekom kateterske ablacije za fibrilaciju atrija (vidjeti dio 4.3).
English: The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin.
Croatian: Incidencija velikog gastrointestinalnog krvarenja prema ISTH (uključujući krvarenje u gornjem odnosno donjem dijelu GI trakta i rektalno krvarenje) iznosila je 0,76% na godinu za apiksaban i 0,86% na godinu za varfarin.
English: Blood and lymphatic system disorders Anaemia
Croatian: Poremećaji krvi i limfnog sustava Anemija često često
English: A total of 8,464 patients were randomised in two pivotal, double-blind, multi-national studies, comparing apixaban 2.5 mg given orally twice daily (4,236 patients) or enoxaparin 40 mg once daily (4,228 patients).
Croatian: Ukupno su 8464 bolesnika randomizirana u dva pivotalna, dvostruko slijepa, multinacionalna ispitivanja u kojima se apiksaban u dozi od 2,5 mg primijenjen peroralno dvaput na dan (4236 bolesnika) uspoređivao s enoksaparinom u dozi od 40 mg jedanput na dan (4228 bolesnika).
English: Dose: mg twice daily
Croatian: Doza: mg dvaput na dan
English: Name and address of the manufacturer(s) responsible for batch release
Croatian: Naziv(i) i adresa(e) proizvođača odgovoran(ih) za puštanje serije lijeka u promet
English: In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6% in the apixaban vs enoxaparin/warfarin study and 13.3% in the apixaban vs placebo study (see section 5.1).
Croatian: U ispitivanjima VTEt, ukupna incidencija nuspojava povezanih s krvarenjem pri primjeni apiksabana iznosila je 15,6% u ispitivanju apiksabana u odnosu na enoksaparin/varfarin te 13,3% u ispitivanju apiksabana u odnosu na placebo (vidjeti dio 5.1).
English: Following administration of the two medicinal products together, mean apixaban AUC and Cmax were 15% and 18% lower than when administered alone.
Croatian: Nakon istodobne primjene navedenih dvaju lijekova srednja vrijednost AUC-a je bila 15% niža, a Cmax 18% niža nego kad su ti lijekovi primijenjeni samostalno.
English: The safety of apixaban has been investigated in 4 Phase III clinical studies including more than 15,000 patients: more than 11,000 patients in NVAF studies and more than 4,000 patients in the VTE treatment (VTEt) studies, for an average total exposure of 1.7 years and 221 days respectively (see section 5.1).
Croatian: Sigurnost primjene apiksabana ispitana je u 4 klinička ispitivanja faze 3 koja su uključivala više od 15 000 bolesnika: više od 11 000 bolesnika u ispitivanjima NVAF, u kojima je prosječna ukupna izloženost bila 1,7 godina i u više od 4000 bolesnika u ispitivanjima liječenja VTE (VTEt), u kojima je prosječna ukupna izloženost bila 221 dan (vidjeti dio 5.1).
English: † Clinically Relevant Non-Major
Croatian: † Klinički značajno, ne veliko
English: Bleeding: - in your brain or in your spinal column - in your lungs
Croatian: - Krvarenje: - u mozgu ili kralježnici - u plućima
English: It is not recommended in patients with severe hepatic impairment (see section 5.2).
Croatian: Ne preporučuje se u bolesnika s teškim oštećenjem jetre (vidjeti dio 5.2).
English: Eliquis is used in adults: - to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor.
Croatian: U odraslih se Eliquis koristi: - za sprječavanje nastanka krvnog ugruška u srcu u bolesnika s nepravilnim otkucajima srca (fibrilacija atrija) u kojih postoji još barem jedan dodatan čimbenik rizika.
English: Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 7).
Croatian: Statistički značajna superiornost utvrđena je i u obje ključne sekundarne mjere ishoda, velikom krvarenju i smrti zbog bilo kojeg uzroka (vidjeti Tablicu 7).
English: Alu-PVC/PVdC perforated unit dose blisters of 100x1 film coated tablets.
Croatian: Al PVC/PVdC perforirani blisteri s jediničnim dozama sa 100 x 1 filmom obloženom tabletom.
English: In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in the apixaban vs warfarin study and 9.6% in the apixaban vs acetylsalicylic acid study.
Croatian: U ispitivanjima NVAF, ukupna incidencija nuspojava povezanih s krvarenjem pri primjeni apiksabana iznosila je 24,3% u ispitivanju apiksabana u odnosu na varfarin te 9,6% u ispitivanju apiksabana u odnosu na acetilsalicilatnu kiselinu.
English: Coadministration of apixaban 10 mg with atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban.
Croatian: Istodobna primjena apiksabana u dozi od 10 mg s atenololom u dozi od 100 mg nije imala klinički značajan učinak na farmakokinetiku apiksabana.
English: It is not recommended in patients with severe hepatic impairment (see sections 4.4. and 5.2).
Croatian: Ne preporučuje se u bolesnika s teškim oštećenjem jetre (vidjeti dijelove 4.4 i 5.2).
English: The recommended dose of apixaban for the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily.
Croatian: Preporučena doza apiksabana u prevenciji ponavljajućih DVT i PE je 2,5 mg peroralno dvaput na dan.
English: The following medicines may increase the effects of Eliquis and increase the chance for unwanted bleeding: - some medicines for fungal infections (e.g., ketoconazole, etc.) - some antiviral medicines for HIV / AIDS (e.g., ritonavir) - other medicines that are used to reduce blood clotting (e.g., enoxaparin, etc.) - anti-inflammatory or pain medicines (e.g., acetylsalicylic acid or naproxen).
Croatian: Sljedeći lijekovi mogu pojačati učinke lijeka Eliquis i povećati rizik od neželjena krvarenja: - neki lijekovi za liječenje gljivičnih infekcija (npr. ketokonazol itd.) - neki antivirusni lijekovi za liječenje HIV infekcije / SIDA-e (npr. ritonavir) - drugi lijekovi koji se koriste za smanjenje zgrušavanja krvi (npr. enoksaparin itd.) - protuupalni lijekovi ili lijekovi za ublažavanje bolova (npr. acetilsalicilatna kiselina ili naproksen).
English: To prevent blood clots from forming after hip or knee replacement operations.
Croatian: Sprječavanje nastanka krvnih ugrušaka nakon operacije ugradnje umjetnog zgloba kuka ili koljena.
English: The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening.
Croatian: Preporučena doza je jedna tableta dvaput na dan, primjerice, jedna ujutro i jedna navečer.
English: Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) A total of 23,799 patients were randomised in the clinical program (ARISTOTLE: apixaban versus warfarin, AVERROES: apixaban versus ASA) including 11,927 randomised to apixaban.
Croatian: U kliničkom je programu randomizirano ukupno 23 799 bolesnika (ARISTOTLE: apiksaban u usporedbi s varfarinom, AVERROES: apiksaban u usporedbi s ASK), uključujući 11 927 bolesnika randomiziranih da primaju apiksaban.
English: Redosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding.
Croatian: Može se razmotriti višekratno doziranje i titriranje doze rekombinantnog faktora VIIa ovisno o poboljšanju krvarenja.
English: For patients initiating treatment with apixaban, 5 mg should be given twice daily for at least 2.5 days (5 single doses) before cardioversion to ensure adequate anticoagulation (see section 5.1).
Croatian: Bolesnici koji započinju liječenje apiksabanom moraju primati dozu apiksabana od 5 mg dvaput na dan tijekom najmanje 2,5 dana (5 pojedinačnih doza) prije kardioverzije kako bi se osigurala prikladna antikoagulacija (vidjeti dio 5.1).
English: Haemodialysis, started two hours after administration of a single dose of apixaban 5 mg, decreased apixaban AUC by 14% in these ESRD subjects, corresponding to an apixaban dialysis clearance of 18 mL/min.
Croatian: Hemodijaliza započeta dva sata nakon primjene jednokratne doze apiksabana od 5 mg smanjila je AUC apiksabana za 14% u bolesnika u terminalnoj fazi bubrežne bolesti, što odgovara klirensu apiksabana kod dijalize od 18 ml/min.
English: Eliquis is used in adults: - to prevent blood clots (deep vein thrombosis [DVT]) from forming after hip or knee replacement operations.
Croatian: U odraslih se Eliquis koristi za: - sprječavanje nastanka krvnih ugrušaka (duboke venske tromboze) nakon operacije ugradnje umjetnog zgloba kuka ili koljena.
English: Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 5).
Croatian: Statistički značajna superiornost utvrđena je i u obje ključne sekundarne mjere ishoda, značajnom krvarenju i smrti zbog bilo kojeg uzroka (vidjeti Tablicu 5).
English: If bleeding occurs, surgery, blood transfusions, or other treatments that may reverse anti-factor Xa activity may be required.
Croatian: Ako dođe do krvarenja, možda će biti potreban kirurški zahvat, transfuzija krvi ili druge vrste liječenja kojima se može poništiti blokirajući učinak lijeka Eliquis na faktor Xa.
English: • Management of overdose situations and haemorrhage
Croatian: • Liječenje predoziranja i zbrinjavanje krvarenja
English: • Necessity to carry the Patient alert card with them at all times
Croatian: • Nužnost da bolesnik sa sobom uvijek nosi Karticu s upozorenjima za bolesnika
English: It is recommended to be used with caution in conditions with increased risk of haemorrhage.
Croatian: Ovaj lijek se preporučuje primjenjivati uz oprez kod bolesti kod kojih postoji povećan rizik od krvarenja.
English: Talk to your doctor, pharmacist or nurse before you take this medicine if you have any of the following: - an increased risk of bleeding, such as: bleeding disorders, including conditions resulting in reduced platelet activity very high blood pressure, not controlled by medical treatment you are older than 75 years you weigh 60 kg or less
Croatian: - povećan rizik od krvarenja, poput: poremećaja krvarenja, uključujući stanja koja uzrokuju smanjenu aktivnost trombocita vrlo visok krvni tlak koji se liječenjem ne drži pod kontrolom ako ste stariji od 75 godina ako težite 60 kg ili manje
English: Use of thrombolytic agents for the treatment of acute ischemic stroke There is very limited experience with the use of thrombolytic agents for the treatment of acute ischemic stroke in patients administered apixaban.
Croatian: Primjena trombolitičkih lijekova u liječenju akutnog ishemijskog moždanog udara Iskustvo s primjenom trombolitičkih lijekova u liječenju akutnog ishemijskog moždanog udara u bolesnika koji uzimaju apiksaban vrlo je oskudno.
English: This exploratory study showed comparable efficacy and safety between apixaban and heparin and/or VKA treatment groups in the setting of cardioversion.
Croatian: Ovo eksplorativno ispitivanje pokazalo je pri kardioverziji usporedivu djelotvornost i sigurnost između skupine liječene apiksabanom i skupine liječene heparinom i/ili antagonistom vitamina K.
English: Haemorrhage risk
Croatian: Relativan rizik
English: In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR≥ 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.
Croatian: U ispitivanju AMPLIFY randomizirano je ukupno 5395 bolesnika u skupine koje su liječene apiksabanom u dozi od 10 mg dvaput na dan peroralno tijekom 7 dana, nakon čega je slijedio apiksaban 5 mg dvaput na dan peroralno tijekom 6 mjeseci, ili enoksaparin 1 mg/kg dvaput na dan potkožno barem 5 dana (do INR 2) i varfarin (ciljni raspon INR 2,0-3,0) peroralno tijekom 6 mjeseci.
English: Adjudicated ISTH major gastrointestinal bleeding occurred in 1 (0.1%) apixaban-treated patient at the 5 mg twice daily dose, no patients at the 2.5 mg twice daily dose, and 1 (0.1%) placebo-treated patient.
Croatian: Utvrđeno veliko gastrointestinalno krvarenje prema ISTH pojavilo se u 1 (0,1%) bolesnika liječenog apiksabanom pri dozi od 5 mg dvaput na dan, nijednom bolesniku pri dozi od 2,5 mg dvaput na dan i u 1 (0,1%) bolesniku liječenom placebom.
English: The safety endpoints of major bleeding, the composite of major and clinically relevant non-major (CRNM) bleeding, and all bleeding showed similar rates for patients treated with apixaban 2.5 mg compared with enoxaparin 40 mg (see Table 5).
Croatian: Sigurnosni ishodi koji uključuju značajno krvarenje, kombinaciju većeg i klinički značajnog koje nije veliko krvarenje te sva krvarenja, imali su podjednake stope u bolesnika liječenih apiksabanom u dozi od 2,5 mg u usporedbi s bolesnicima liječenim enoksaparinom u dozi od 40 mg (vidjeti Tablicu 5).
English: As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR and activated partial thromboplastin time (aPTT).
Croatian: Zahvaljujući inhibiciji faktora Xa apiksaban produljuje parametre testova zgrušavanja poput protrombinskog vremena (PV), INR-a i aktiviranog parcijalnog tromboplastinskog vremena (aPTV).
English: The recommended dose of apixaban is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL (133 micromole/L).
Croatian: Preporučena doza apiksabana je 2,5 mg peroralno dvaput na dan u bolesnika s nevalvularnom fibrilacijom atrija koji imaju barem dvije od sljedećih značajki: dob ≥ 80 godina, tjelesnu težinu ≤ 60 kg ili vrijednost kreatinina u serumu ≥ 1,5 mg/dl (133 mikromola/l).
English: Interaction with inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir).
Croatian: Interakcija s inhibitorima izoenzima 3A4 citokroma P450 (CYP3A4) i P-glikoproteina (P-gp) Primjena lijeka Eliquis ne preporučuje se u bolesnika koji istodobno primaju sistemsku terapiju lijekovima koji su snažni inhibitori CYP3A4 i P-gp-a, poput azolnih antimikotika (npr. ketokonazol, itrakonazol, vorikonazol i posakonazol) i inhibitora HIV proteaze (npr. ritonavir).
English: Anti-Xa Activity Max (IU/mL)
Croatian: Najviša anti-Xa aktivnost apiksabana (IU/ml)
English: * All the bleeding criteria included surgical site bleeding 1 Includes events occurring after first dose of enoxaparin (pre-surgery) 2 Includes events occurring after first dose of apixaban (post-surgery)
Croatian: Uključuje događaje koji su nastupili nakon prve doze enoksaparina (prije kirurškog zahvata) Uključuje događaje koji su nastupili nakon prve doze apiksabana (nakon kirurškog zahvata)
English: Haemodialysis decreased apixaban AUC by 14% in subjects with end-stage renal disease (ESRD), when a single dose of apixaban 5 mg was administered orally.
Croatian: Hemodijaliza je smanjila AUC apiksabana za 14% u bolesnika u terminalnoj fazi bubrežne bolesti (engl. end-stage renal disease, ESRD) kod peroralne primjene jednokratne doze od 5 mg apiksabana.
English: Switching from vitamin K antagonist (VKA) therapy to Eliquis When converting patients from vitamin K antagonist (VKA) therapy to Eliquis, warfarin or other VKA therapy should be discontinued and Eliquis started when the international normalised ratio (INR) is < 2.
Croatian: Prelazak terapije antagonistima vitamina K na Eliquis Kad bolesnik prelazi s terapije antagonistom vitamina K na Eliquis, liječenje varfarinom ili drugim antagonistom vitamina K treba prekinuti i započeti primjenu lijeka Eliquis kad međunarodni normalizirani omjer (INR) bude < 2.
English: - bruising and swelling - Nausea (feeling sick)
Croatian: - nastanak modrica i oticanje - Mučnina
English: In the ARISTOTLE study a total of 18,201 patients were randomised to double-blind treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [4.7%], see section 4.2) or warfarin (target INR range 2.0-3.0), patients were exposed to study drug for a mean of 20 months.
Croatian: U ispitivanju ARISTOTLE je ukupno 18 201 bolesnik randomiziran na dvostruko slijepo liječenje apiksabanom u dozi od 5 mg dvaput na dan (ili 2,5 mg dvaput na dan u odabranih bolesnika [4,7%], vidjeti dio 4.2) ili varfarinom (ciljni raspon INR-a 2,0-3,0).
English: Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTEt)
Croatian: Liječenje DVT i PE te prevencija ponavljajućih DVT i PE (VTEt)
English: The safety of apixaban has been investigated in 7 Phase III clinical studies including more than 21,000 patients: more than 5,000 patients in VTEp studies, more than 11,000 patients in NVAF studies and more than 4,000 patients in the VTE treatment (VTEt) studies, for an average total exposure of 20 days, 1.7 years and 221 days respectively (see section 5.1).
Croatian: Sigurnost primjene apiksabana ispitana je u 7 kliničkih ispitivanja faze 3 koja su uključivala više od 21 000 bolesnika: više od 5000 bolesnika u ispitivanjima VTEp, u kojima je prosječna ukupna izloženost bila 20 dana, više od 11 000 bolesnika u ispitivanjima NVAF, u kojima je prosječna ukupna izloženost bila 1,7 godina i u više od 4000 bolesnika u liječenju VTE (VTEt), u kojima je prosječna ukupna izloženost bila 221 dan (vidjeti dio 5.1).
English: The dosing regimen should be reduced to 2.5 mg apixaban given twice daily for at least 2.5 days (5 single doses) if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment).
Croatian: Režim doziranja potrebno je smanjiti na 2,5 mg apiksabana primijenjenih dvaput na dan tijekom najmanje 2,5 dana (5 pojedinačnih doza) ako bolesnik ispunjava kriterije za smanjenje doze (vidjeti dijelove Smanjenje doze i Oštećenje bubrežne funkcije u prethodnom tekstu).
English: Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.
Croatian: Stoga nije vjerojatno da će hemodijaliza biti učinkovita u slučaju predoziranja apiksabanom.
English: Inducers of CYP3A4 and P-gp
Croatian: Induktori citokroma CYP3A4 i P-gp-a
English: Prevention of stroke and systemic embolism in adult patients with NVAF, with one or more risk factors (NVAF)
Croatian: Prevencija moždanog udara i sistemske embolije u odraslih bolesnika s nevalvularnom fibrilacijom atrija, koji imaju jedan ili više čimbenika rizika (NVAF)
English: Efficacy across subgroups, including age, gender, body mass index (BMI), renal function, extent of index PE, location of DVT thrombus, and prior parenteral heparin use was generally consistent.
Croatian: Djelotvornost u podskupinama, uključujući dob, spol, indeks tjelesne mase (BMI), bubrežnu funkciju, obim indeksa plućne embolije, lokaciju tromba u DVT i prethodnu primjenu parenteralnog heparina bila je općenito slična.